Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions

C-r Pradeep, Amit Zeisel, Wolfgang J. Köstler, Mattia Lauriola, Jasmine Jacob‐Hirsch, Benjamin Haibe-Kains, Ninette Amariglio, Nir Ben‐Chetrit, Anna Emde, Inna Solomonov, Gera Neufeld, Martine Piccart, Irit Sagi, Christos Sotiriou, Gideon Rechavi, Eytan Domany, Christine Desmedt, Yosef YardenOncogene 2024 · DOI · OpenAlex

Introduction

This document serves as a formal correction to a 2011 study published in Oncogene. The primary objective is to rectify an image duplication error in Figure 1a. Despite this clerical correction, the authors emphasize that the original quantitative data and the fundamental conclusions regarding the mechanisms of breast cancer progression remain unchanged.

The Challenge of Cancer Progression

A central question in oncology is how premalignant lesions—cells harboring initial mutations—transition into invasive, life-threatening tumors. This research specifically examines HER2-positive lesions. While HER2 overexpression is a known driver of breast cancer, it is often insufficient on its own to trigger invasive behavior. The study investigates how external growth factors (GFs), specifically Epidermal Growth Factor (EGF), act as environmental triggers that cooperate with genetic mutations to drive invasion.

Methodology

The study utilized the MCF10A human mammary epithelial cell line as a "normal" model, alongside a variant engineered to overexpress HER2 (MCF10A-HER2). To quantify invasiveness, a Transwell Invasion Assay was employed:

  1. Barrier Setup: Cells were seeded onto a Transwell filter coated with Matrigel, which simulates the extracellular matrix.
  2. Stimulation: Experimental groups were treated with EGF (20 ng/ml).
  3. Detection: After 12 hours, cells that successfully invaded through the Matrigel and migrated to the opposite side of the filter were stained with crystal violet.
  4. Quantification: The extent of invasion was measured via optical density (OD).

Key Insights: The Synergy of HER2 and EGF

The corrected Figure 1a illustrates a critical concept in cancer biology: synergy between internal genetic states and external signals.

Figure 1a: Microscopic visualization of cell invasion in MCF10A and MCF10A-HER2 cells with and without EGF treatment.
  • HER2 as a Primer: Overexpression of HER2 alone (bottom-left) induces some cellular changes but does not lead to widespread invasion in the absence of external growth factors.
  • EGF as a Trigger: The addition of EGF to HER2-overexpressing cells (bottom-right) results in a dramatic, non-linear increase in invasive capacity.
  • Multi-Hit Hypothesis: These findings support the "multi-hit" model of cancer progression, where a genetic mutation (HER2) primes the cell, and an environmental signal (EGF) propels it toward malignancy.

Quantitative Results

The quantitative data presented in the bar graph corroborates the visual evidence from the microscopic images.

Figure 1b: Quantitative analysis of relative cell invasion (OD) across experimental groups.
  • Control MCF10A: Showed negligible invasion regardless of EGF presence.
  • MCF10A-HER2 (No EGF): Exhibited a baseline invasion level (OD ~0.2).
  • MCF10A-HER2 (+ EGF): Demonstrated a massive surge in invasion (OD ~0.45), more than doubling the invasive capacity compared to the HER2-only group.

Conclusion

This correction reinforces the integrity of the original study's findings. The data suggests that blocking external growth factor signals could be a viable strategy for preventing HER2-positive premalignant lesions from progressing to invasive disease. While the in vitro Matrigel model has limitations in replicating the full complexity of the human breast environment, it provides a robust framework for understanding the molecular drivers of cancer progression.

Summary updated

BibTeX
@inproceedings{pradeep2024correction,
  author = {C-R Pradeep and Amit Zeisel and Wolfgang J. Köstler and Mattia Lauriola and Jasmine Jacob‐Hirsch and Benjamin Haibe-Kains and Ninette Amariglio and Nir Ben‐Chetrit and Anna Emde and Inna Solomonov and Gera Neufeld and Martine Piccart and Irit Sagi and Christos Sotiriou and Gideon Rechavi and Eytan Domany and Christine Desmedt and Yosef Yarden},
  title = {{Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions}},
  booktitle = {Oncogene},
  year = {2024},
  doi = {10.1038/s41388-024-02990-w},
}
Figure